Abstract 508P
Background
Transarterial radioembolization (TARE) represents a minimally invasive interventional radiation therapy, integrating embolization and radiation for cancer treatment. This meta-analysis seeks to systematically compare the efficacy and safety of the transradial approach (TRA) against the transfemoral approach (TFA) in the context of TARE for liver tumors.
Methods
We conducted an extensive search across multiple databases, including PubMed, SCOPUS, Cochrane, EMBASE, and Web of Science, to identify pertinent clinical trials and observational studies. The focus was on studies comparing the transradial approach (TRA) versus the transfemoral approach (TFA) for transarterial radioembolization (TARE) in the treatment of liver tumors. Pooled results were scrutinized for various parameters, encompassing procedure time, fluoroscopy time, air kerma (mGy), dose-area product (DAP, mGy-cm2), pain in the recovery room post-procedure, overall pain during the procedure, and adverse events.The quality assessment of the included studies was conducted using Cochrane's Risk of Bias 2 tool for randomized clinical trials (RCTs) and the Newcastle-Ottawa Scale for cohort studies. Subsequently, data analysis was performed utilizing the REVMAN 5.4.1. software.
Results
Six studies, encompassing one RCT and five cohort studies and involving a total of 1,209 patients, underwent comprehensive analysis. The aggregated findings revealed a notable reduction in procedure duration associated with the TRA (MD = -6.30, 95% CI [-9.88 to -2.73], P = 0.005). However, no statistically significant disparities were identified between TRA and the TFA in terms of fluoroscopy time, air kerma, DAP, pain in the recovery room, pain overall during the procedure, and adverse events (P = 0.50, P = 0.76, P = 0.96, P = 0.40, P = 0.49, P=0.62, respectively).
Conclusions
Our results indicate that bothTRA and TFA exhibit comparable safety and efficacy in the context of TARE for liver tumors. Notably, TRA holds the advantage of a significantly shorter procedure duration.
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.